收藏切换
Cost-effectiveness analysis of nintedanib esylate in the treatment of idiopathic pulmonary fibrosis
收藏切换
Jiahao HU1, Yuhan LIU1, Xingming PAN2, Chunlin JIN1, Fen LI1, *
World Clinical Drug | 2023, 44(9) : 981 - 989
Less
收藏切换
World Clinical Drug | 2023, 44(9): 981-989
• Article •
Cost-effectiveness analysis of nintedanib esylate in the treatment of idiopathic pulmonary fibrosis
Full
Jiahao HU1, Yuhan LIU1, Xingming PAN2, Chunlin JIN1, Fen LI1, *
Affiliations
  • 1.Shanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai 200040, China
  • 2.International School of Pharmaceutical Business, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
Published: 2023-09-10 doi: 10.13683/j.wph.2023.09.015
Outline
收藏切换
Objective

To evaluate the cost-effectiveness analysis of nintedanib esylate in the treatment of idiopathic pulmonary fibrosis (IPF).

Methods

From the perspective of Chinese healthcare system, a Markov model was constructed to evaluate the cost-effectiveness of nintedanib esylate compared with pirfenidone in the treatment of IPF patients. The model cycle was one month using a lifetime horizon. The discount rate of both cost and effectiveness was 5%. One-way sensitivity analysis, probabilistic sensitivity analysis and scenario analysis were used to verify the robustness of the base case results.

Results

The results of the base case showed that compared with generic pirfenidone, nintedanib esylate had lower costs and higher quality-adjusted life years output in the treatment of IPF patients, which had absolute advantages and was a more economical program. The conclusion was verified in one-way sensitivity analysis, probabilistic sensitivity analysis and scenario analysis.

Conclusion

Nintedanib esylate is a cost-effective alternative compared with generic pirfenidone in Chinese patients with IPF.

nintedanib esylate  /  idiopathic pulmonary fibrosis  /  cost-effectiveness analysis  /  pirfenidone
胡嘉浩, 刘宇晗, 潘星明, 金春林, 李芬. 乙磺酸尼达尼布用于特发性肺纤维化治疗的成本-效果分析. 世界临床药物, 2023 , 44 (9) : 981 -989 . DOI: 10.13683/j.wph.2023.09.015
Jiahao HU, Yuhan LIU, Xingming PAN, Chunlin JIN, Fen LI. Cost-effectiveness analysis of nintedanib esylate in the treatment of idiopathic pulmonary fibrosis[J]. World Clinical Drug, 2023 , 44 (9) : 981 -989 . DOI: 10.13683/j.wph.2023.09.015
Year 2023 volume 44 Issue 9
11
1
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.09.015
  • Receive Date:2023-02-14
  • Online Date:2026-11-18
  • Published:2023-09-10
Article Data
Affiliations
History
  • Received:2023-02-14
Affiliations
    1.Shanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai 200040, China
    2.International School of Pharmaceutical Business, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.09.015
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT